UROLOGICAL SURVEY   ( Download pdf )

 

PATHOLOGY

Inflammatory Myofibroblastic Tumors of the Urinary Tract: A Clinicopathologic Study of 46 Cases, Including a Malignant Example Inflammatory Fibrosarcoma and a Subset Associated With High-Grade Urothelial Carcinoma
Montgomery EA, Shuster DD, Burkart AL, Esteban JM, Sgrignoli A, Elwood L, Vaughn DJ, Griffin CA, Epstein JI
Department of Pathology, Johns Hopkins Hospital, Baltimore, USA
Am J Surg Pathol. 2006; 30: 1502-12

  • Inflammatory myofibroblastic tumor (IMT) of the urinary tract, also termed postoperative spindle cell nodule, inflammatory pseudotumor, and pseudosarcomatous fibromyxoid tumor, is rare and in the past was believed to reflect diverse entities. We reviewed a series of 46 IMTs arising in the ureter, bladder, and prostate, derived primarily from a large consultation practice. There were 30 male and 16 females aged 3 to 89 years (mean 53.6). Lesions were 1.2 to 12 cm (mean 4.2). There was a history of recent prior instrumentation in 8 cases. Morphology was similar to that previously described for IMT occurring in this region, with the exception of 1 case that focally appeared sarcomatous. Polypoid cystitis coexisted in 5 patients (11%). Mitoses were typically scant (0 to 20/10 hpf, mean 1). Necrosis was seen in 14 (30%) cases. Invasion of the muscularis propria was documented in 19 (41%). By immunohistochemistry (IHC), lesions at least focally expressed anaplastic lymphoma kinase (ALK) (20/35, 57%), AE1/3 (25/34, 73%), CAM5.2 (10/15, 67%), CK18 (6/6, 100%), actin (23/25, 92%), desmin (15/19, 79%), calponin (6/7, 86%), caldesmon (4/7, 57%, rare cells), p53 (10/13, 77%), and most lacked S100 (0/14), CD34 (0/13), CD117 (2/13, 15%), CD21 (0/5), and CD23 (0/3). ALK gene alterations were detected by fluorescence in situ hybridization (FISH) in 13/18 (72%) tested cases, including 2 with prior instrumentation; 13/18 (72%) showed agreement between FISH ALK results and ALK protein results by IHC. Most bladder IMTs were managed locally, but partial cystectomy was performed as the initial management in 7 cases and cystectomy in 1 (1 IMT was initially misinterpreted as carcinoma, 1 IMT was found incidentally as a separate lesion in a cystectomy specimen performed for urothelial carcinoma). Follow-up was available in 32 cases (range 3 to 120 mo; mean 33; median 24). There were 10 patients with recurrences (2 with 2 recurrences). Recurrences were unassociated with muscle invasion or with ALK alterations. In 2 cases, tumors of the urinary tract (TURs) showing IMT preceded (1 and 2 mo, respectively) TURs showing sarcomatoid carcinoma with high-grade invasive urothelial carcinoma accompanied with separate fragments of IMT. Even on re-review the IMT in these 2 cases were morphologically indistinguishable from other cases of IMT, with FISH demonstrating ALK alterations in the IMT areas in one of them. Both these patients died of their carcinomas. Lastly, there was 1 tumor with many morphological features of IMT and an ALK rearrangement, yet overtly sarcomatous. This case arose postirradiation for prostate cancer 4 years before the development of the lesion, with tumor recurrence at 4 months and death from intra-abdominal metastatic disease at 9 months. In summary, urinary tract IMTs are rare and share many features with counterparts in other sites, displaying similar morphology and immunogenotypic features whether de novo or postinstrumentation. Typical IMTs can be locally aggressive, sometimes requiring radical surgical resection, but none of our typical cases metastasized, although they can rarely arise contemporaneously with sarcomatoid urothelial carcinomas. For these reasons, close follow-up is warranted.

  • Editorial Comment
    It is controversial in the literature whether inflammatory myofibroblastic tumor of the urinary tract is an inflammatory or a neoplastic lesion. This is the reason for the vast list of synonyms: reactive pseudosarcomatous response, postoperative spindle cell nodule, inflammatory pseudotumor, nodular fasciitis, pseudomalignant spindle cell proliferation, pseudosarcomatous myofibroblastic proliferation, pseudosarcomatous myofibroblastic tumor, and inflammatory myofibroblatic tumor.
    The lesion mimics both sarcomas and spindled carcinomas, the latter compounded by their expression of various cytokeratins (1). Considering that the lesion in the urinary tract has been benign in almost all series it would be similar to nodular fasciitis elsewhere. However, it differs by nodular fasciitis in its capacity to infiltrate deeply into the detrusor muscle (2).
    The identification of ALK alterations in bladder lesions suggests that, despite the frequent similarity to nodular fasciitis, inflammatory myofibroblastic tumor is neoplastic (3). There is a clonal aberration typically involving chromosome 2p. This results in rearrangement of the ALK gene which codifies a receptor of tyrosine-kinase and hence over-expression of ALK-1 protein. This over-expression of the ALK protein is also seen in anaplastic large cell lymphomas.


References
1. Freeman A, Geddes N, Munson P, Joseph J, Ramani P, Sandison A, et al.: Anaplastic lymphoma kinase (ALK 1) staining and molecular analysis in inflammatory myofibroblastic tumours of the bladder: a preliminary clinicopathological study of nine cases and review of the literature. Mod Pathol. 2004; 17: 765-71.
2. Billis A: Weekly conference with the residents. Case 21. Available: http://www.fcm.unicamp.br/deptos/anatomia/casosdeuro/casosdeuroentrada.html.
3. Tsuzuki T, Magi-Galluzzi C, Epstein JI: ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol. 2004; 28: 1609-14.

Dr. Athanase Billis
Full-Professor of Pathology
State University of Campinas, Unicamp
Campinas, Sao Paulo, Brazil